Study identifier:D3560L00071
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
OPtimal Type 2 dIabetes Management Including benchmarking and Standard trEatment.
diabetes
-
No
-
All
4027
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
Demonstrate that the use of benchmarking improves quality of patient care, in particular the control of diabetes, lipids and blood pressure, by determining the percentage of patients in the benchmarking group achieving pre-set targets for HbA1c 14,18, LDL-cholesterol16,18 and Systolic Blood Pressure17,18 versus control group (non-benchmarking group) after 12 months of follow-up.
Location
Location
AALST, Belgium
Location
AARSCHOT, Belgium
Location
ALSEMBERG, Belgium
Location
AMAY, Belgium
Location
ANTOING, Belgium
Location
ANTWERPEN, Belgium
Location
ANZEGEM, Belgium
Location
ATH, Belgium
Arms | Assigned Interventions |
---|---|
1 Control group | - |
2 Benchmarking group | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.